OBJECTIVES: Macrophage migration inhibitory factor (MIF) promotes leukocyte recruitment and antagonizes the anti-inflammatory effects of glucocorticoids (GC). The aim of this study was to examine whether interaction between MIF and GC underlies the ability of MIF to promote leukocyte-endothelial cell (EC) interactions. METHODS: Intravital microscopy was used to assess leukocyte-EC interactions in wild-type and MIF(-/-) mice following treatment with lipopolysaccharide (LPS), the GC dexamethasone, and inhibition of endogenous GC, using the GC-receptor antagonist, RU486. RESULTS: Dexamethasone reduced LPS-induced leukocyte interactions in wild-type mice to levels similar to those observed in MIF(-/-) mice not treated with dexamethasone, whereas in MIF(-/-) mice, leukocyte interactions were not further inhibited by dexamethasone. RU486 increased LPS-induced leukocyte adhesion and emigration to a similar extent in both wild-type and MIF(-/-) mice, indicating that endogenous GC exert a similar inhibitory effect on leukocyte trafficking in wild-type and MIF(-/-) mice. Both MIF deficiency and RU486 treatment reduced VCAM-1 expression, while neither treatment modulated expression of ICAM-1 or chemokines CCL2, KC, and MIP-2. CONCLUSIONS: These results suggest that endogenous MIF and GC regulate leukocyte-EC interactions in vivo reciprocally but through predominantly independent mechanisms, and that the anti-inflammatory effect of MIF deficiency is comparable to that of exogenous GC.
OBJECTIVES:Macrophage migration inhibitory factor (MIF) promotes leukocyte recruitment and antagonizes the anti-inflammatory effects of glucocorticoids (GC). The aim of this study was to examine whether interaction between MIF and GC underlies the ability of MIF to promote leukocyte-endothelial cell (EC) interactions. METHODS: Intravital microscopy was used to assess leukocyte-EC interactions in wild-type and MIF(-/-) mice following treatment with lipopolysaccharide (LPS), the GC dexamethasone, and inhibition of endogenous GC, using the GC-receptor antagonist, RU486. RESULTS:Dexamethasone reduced LPS-induced leukocyte interactions in wild-type mice to levels similar to those observed in MIF(-/-) mice not treated with dexamethasone, whereas in MIF(-/-) mice, leukocyte interactions were not further inhibited by dexamethasone. RU486 increased LPS-induced leukocyte adhesion and emigration to a similar extent in both wild-type and MIF(-/-) mice, indicating that endogenous GC exert a similar inhibitory effect on leukocyte trafficking in wild-type and MIF(-/-) mice. Both MIF deficiency and RU486 treatment reduced VCAM-1 expression, while neither treatment modulated expression of ICAM-1 or chemokines CCL2, KC, and MIP-2. CONCLUSIONS: These results suggest that endogenous MIF and GC regulate leukocyte-EC interactions in vivo reciprocally but through predominantly independent mechanisms, and that the anti-inflammatory effect of MIF deficiency is comparable to that of exogenous GC.
Authors: Christian Weber; Sandra Kraemer; Maik Drechsler; Hongqi Lue; Rory R Koenen; Aphrodite Kapurniotu; Alma Zernecke; Jürgen Bernhagen Journal: Proc Natl Acad Sci U S A Date: 2008-10-13 Impact factor: 11.205
Authors: N Marui; M K Offermann; R Swerlick; C Kunsch; C A Rosen; M Ahmad; R W Alexander; R M Medford Journal: J Clin Invest Date: 1993-10 Impact factor: 14.808
Authors: J Bernhagen; T Calandra; R A Mitchell; S B Martin; K J Tracey; W Voelter; K R Manogue; A Cerami; R Bucala Journal: Nature Date: 1993-10-21 Impact factor: 49.962
Authors: Huapeng Fan; Pam Hall; Leilani L Santos; Julia L Gregory; Gunter Fingerle-Rowson; Richard Bucala; Eric F Morand; Michael J Hickey Journal: J Immunol Date: 2011-03-16 Impact factor: 5.422
Authors: Leilani L Santos; Huapeng Fan; Pam Hall; Devi Ngo; Charles R Mackay; Gunter Fingerle-Rowson; Richard Bucala; Michael J Hickey; Eric F Morand Journal: Arthritis Rheum Date: 2011-04
Authors: Albert Dahdah; Jillian Johnson; Sreejit Gopalkrishna; Robert M Jaggers; Darren Webb; Andrew J Murphy; Nordin M J Hanssen; Beatriz Y Hanaoka; Prabhakara R Nagareddy Journal: Front Cell Dev Biol Date: 2022-03-02